Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference102 articles.
1. Population-based estimates of survival among elderly patients with brain metastases;Lamba;Neuro Oncol,2021
2. Comparison of the survival time in the non-small cell lung cancer patients with different organ metastasis;Wu;Zhongguo Fei Ai Za Zhi,2019
3. Treatment of brain metastases of non-small cell lung carcinoma;Rybarczyk-Kasiuchnicz;Int J Mol Sci,2021
4. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset;Ohe;Jpn J Clin Oncol,2019
5. Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer;Nagano;Curr Cancer Drug Targets,2018
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Combined use of TLR4 and TLR7/8 agonists to improve the efficacy of immune checkpoint inhibitors in “hot” tumor treatment and the establishment of long-term immune protection;2023-12-13
2. The DC–T cell axis is an effective target for the treatment of non‐small cell lung cancer;Immunity, Inflammation and Disease;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3